Patent-Approval Linkage System and Health Insurance: Supplementing the System to Promote Innovation and Prevent Public Financial Loss

Euntae Park; Jinok Byeon

doi:10.17000/kspr.23.4.201612.93

There has been a controversial debate over positive and negative impacts of the patent-approval linkage system adopted by the FTA between the United States and Korea. As drug price is closely connected to the introduction of generic drug, the patent-approval linkage system could result in the loss of public finance by delaying the entry of generic drugs to the market and maintaining an exclusive price of brand name drugs for a long duration. For these reasons, the Ministry of Health and Welfare worked on a partial amendment of the National Health Insurance Act that allows brand-name drug companies to reimburse the National Health Insurance Service for the loss caused by the overuse of the patent rights. The amendment intends to prevent brand-name companies from causing wrongful financial loss and to prepare the basis regulations for the reimbursement. Although the amendment was not approved, there is still a need for refine the system to reinforce the public interest and reduce the adverse effects of the patent-approval linkage system. In this study, we compared the loss security system in the patent-approval linkage system in Korea, Australia and Canada, and sought to gain implications to improve the system. We also analyzed differences in the characteristics of the health security system, permit authorities and judicature judgments among the three countries, and the study discusses a valid posterior reimbursement system for public loss in Korea.

Citation status

KCI Citation Counts (2)
열림/닫힘 버튼
REFERENCES (29)
열림/닫힘 버튼
* 2021년 이후 발행 논문의 참고문헌은 현재 구축 중입니다.

[journal] 김대중 / 2013 / A Study on the Generic Exclusivity under the Drug Approval-Patent Linkage / 보건경제와 정책연구 / 한국보건경제정책학회 19(1) : 55~75

[report] 김대중 / 2012 / 보건의료분야 시장개방 이슈와 대응방안 연구: 한미FTA 중심으로 / 한국보건사회연구원

[journal] 김현철 / 2012 / Some Considerations about the Applicability of Biologics to the Approval-patent Linkage System in KORUS FTA / 법학논집 / 법학연구소 17(1) : 225~240

[other] 남희섭 / 2014 / 토론문-의약품 허가 특허 연계 제도 / 의약품 허가특허연계제도 관련 약사법 일부개정법률(안)에 대한 공청회

[other] 보건복지부 / 2015 / ｢국민건강보험법 개정안｣ 신설･강화규제 심사안

[other] 보건복지부 / 2015 / 허가-특허 연계 제도 관련 국민건강보험법 개정안 설명자료

[other] 식품의약품안전처 / 2015 / 의약품 허가특허연계제도 해설서

[web] 식품의약품안전처 / 2016 / 의약품 특허 목록 / http://medipatent.mfds.go.kr

[other] 식품의약품안전처 / 2016 / 의약품 허가･특허 연계제도 이해 및 대응과정

[book] 오근엽 / 2010 / 한미 FTA 지재권 협상에 따른 의약품 분야 사회후생변화 / 집문당

[journal] 오승한 / 2012 / Comparative Study on the Patent Linkage System of Major Countries / 법제연구 / 한국법제연구원 (43) : 317~372

[journal] 전성태 / 2014 / Korea-China FTA and Patent linkage System of Phamacy: A Focused on Review of Comparative Law / 한국의료법학회지 / 한국의료법학회 22(2) : 185~204 / http://dx.doi.org/10.17215/kaml.2014.12.22.2.185

[journal] 정연 / 2014 / The effects of stronger protection of intellectual property rights for medicines on pharmaceutical market, price and utilisation: case studies for five countries / 한국사회정책 / 한국사회정책학회 21(2) : 183~228 / 10.17000/kspr.21.2.201406.183

[journal] 정용익 / 2014 / A Study on the Introduce Necessary of the Generic Market Exclusivity under The Drug Approval-Patent Linkage in Korea / 지식재산연구 / 한국지식재산연구원 9(4) : 101~128

[thesis] 정용익 / 2014 / 한국의 법제 특성을 고려한 의약품 허가-특허연계제도의 도입방안 / 박사 / 고려대학교 대학원

[journal] 정윤택 / 2012 / Patent strategy and market competition in the pharmaceutical field / 보건경제와 정책연구 / 한국보건경제정책학회 18(1) : 109~136

[journal] 조재신 / 2015 / A Study on Legislation Amendments and Its Effects in Korea after the Introduction of Patent-Drug Approval Linkage Under Korea-US FTA / 법학연구 / 법학연구소 26(1) : 409~443

[journal] Bhardwaj, R. / 2013 / The impact of patent linkage on marketing of generic drugs / Journal of Intellectual Property Rights 18 : 316~322

[journal] Chen, Q. / 2011 / Destroying a pharmaceutical patent for saving lives? A case study of Sanofi-Synthelabo v. Apotex, Inc / Albany Law Journal of Science and Technology 21(1) : 125~152

[report] Commonwealth of Australia / 2004 / Select committee on the Free Trade Agreement between Australia and the United States of America

[other] Commonwealth of Australia / 2015 / Commonwealth of Australia v Sanofi-Aventis / FCA 384

[journal] Crowne, E. / 2011 / Innovators and generics: proposals for balancing pharmaceutical patent protection and public access to cheaper medicines in Canada / IDEA 51(4) : 719~720

[book] Drexl, J. / 2008 / Intellectual property, market power and the public interest / P.I.E. Peter Lang : 13~33

[journal] Faunce, T. / 2010 / Impact of the Australia–US Free Trade Agreement on Australian medicines regulation and prices / Journal of Generic Medicines 7(1) : 18~29

[journal] Faunce, T. / 2007 / ‘Linkage’ pharmaceutical evergreening in Canada and Australia / Australia New Zealand Health Policy 4(8) : 1~11

[report] Harris, T. / 2013 / Pharmaceutical patents review report / Commonwealth of Australia

[journal] Schankerman, M. / 1998 / How valuable is patent protection? estimates by technology field / The RAND Journal of Economics 29(1) : 77~79

[journal] Shadlen, K. / 2009 / The Politics of patnets and drugs in Brazil and Mexico: The industrial bases of health policies / Comparative Politics 42(1) : 41~58

[other] Troy, D. / 2003 / U.S. Drug price competition and patent term restoration act of 1984 (Hatch-Waxman Amendments) / Food and Drug Administration

KJC Korea
Journal Central

Statistics

Tools

Sharing

Issue List

Citation status